• Injection Depth: Target the superficial dermis using an intradermal technique. The specialized syringe supports controlled, precise delivery in this superficial plane.
• Limitations: Not indicated for deep wrinkle correction or volumization. Refer to STYLAGE® M or L for deeper-plane treatments.
• Pain Management: Lidocaine (3 mg/mL) is co-formulated in the gel to reduce discomfort during injection; additional topical anesthesia remains optional at the practitioner’s discretion.
• Administration Safety: Maintain a strict aseptic technique throughout the procedure and avoid intravascular injection.
• Post-Treatment Guidance: Advise patients to avoid sun exposure until initial redness and swelling completely resolve.
• Key Risks: Key warnings include vascular occlusion, skin necrosis, visual disturbance, and transient bruising at the injection site.

• Can deliver fine line correction, including periorbital lines, perioral lines, and superficial skin texture irregularities.
• Indicated for superficial wrinkle treatment, including the superficial component of nasolabial folds and marionette lines.
• Designed for skin texture refinement in the superficial dermis rather than volumization.
• Prescribed for use by licensed aesthetic medicine professionals only; not for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 16 mg/g; mannitol 9 mg/mL; lidocaine 3 mg/mL.
• Format: Injectable gel supplied in 2 × 0.8 mL prefilled syringes (BI-FLEX® syringe system) with 4 × 30G ½ needles.
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid dermal filler with mannitol and lidocaine; superficial-plane formulation.
• Technology: IPN-Like Technology™; BI-FLEX® syringe system (formerly Bi-SOFT®).
• Regulatory status: CE-marked for EU use; US FDA status should be verified by jurisdiction before procurement.

Contraindications

• Do not administer to patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type anesthetics, or any excipient in the formulation.
• Do not inject into areas with active skin infection or inflammation at the intended treatment site.
• Avoid use during pregnancy or breastfeeding as a precaution, due to limited safety data in these populations.

• Inject into the superficial dermis only; the BI-FLEX® syringe system supports precise placement in the superficial plane.
• Topical anesthesia is optional, as lidocaine 3 mg/mL is already co-formulated in the gel.
• Allow the syringe to reach room temperature before administration.
• The product is intended for single use only; discard any unused gel, syringe, and needle after the procedure.
• Screen for hypersensitivity to hyaluronic acid and amide-type anesthetics before treatment and refer to the full IFU.

STYLAGE® S BI-FLEX® with Lidocaine is a CE-marked medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact Med Supply Solutions support team for sourcing information and documentation support.

1. Ramos-E-Silva M, Fonteles LA, Lagalhard CS, Fucci-da-Costa AP. STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature. Clin Cosmet Investig Dermatol. 2013;6:257-261. Published 2013 Oct 23. doi:10.2147/CCID.S35251
2. Micheels P, Porcello A, Bezzola T, et al. Clinical Perspectives on the Injectability of Cross-Linked Hyaluronic Acid Dermal Fillers: A Standardized Methodology for Commercial Product Benchmarking with Inter-Injector Assessments. Gels. 2024;10(2):101. Published 2024 Jan 26. doi:10.3390/gels10020101

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.